Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Dermatologic 1Breast 1

Conditions

Sarcoma 1Osteosarcoma 1Melanoma 1Carcinoma, Merkel Cell 1Carcinoma, Basal Cell 1Breast Neoplasms 1Bone Neoplasms 1

Interventions

Irinotecan 2Cyclophosphamide 2tocilizumab 1regorafenib 1poly ICLC 1pembrolizumab 1palbociclib 1liposomal doxorubicin 1fludarabine 1flt3 ligand protein 1aldesleukin 1Topotecan 1Temozolomide 1Taxes 1Radiotherapy 1Radiosurgery 1Radiation 1Paclitaxel 1Observation 1Nivolumab 1Lomustine 1Ipilimumab 1Gemcitabine 1Fitness Trackers 1Doxorubicin 1Carboplatin 1CTLA-4 Antigen 1Biopsy, Needle 1Albumin-Bound Paclitaxel 13-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Bone Neoplasms × flt3 ligand protein × Clear all
NCT04616248 2026-01-07

In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors

University of Southern California

Phase 1 Active not recruiting
14 enrolled
BreastDermatologicSarcoma

Bone Neoplasms, Breast Neoplasms, Carcinoma, Basal Cell, Melanoma, Sarcoma, Osteosarcoma, Carcinoma, Merkel Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡